Abstract
Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy-induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid-1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.
Original language | English (US) |
---|---|
Pages (from-to) | 140-142 |
Number of pages | 3 |
Journal | Supportive Cancer Therapy |
Volume | 3 |
Issue number | 3 |
DOIs | |
State | Published - Apr 2006 |
Externally published | Yes |
Keywords
- 5-Hydroxytryptamine-3 receptor antagonists
- Aprepitant
- Casopitant
- Nausea
- Vomiting
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Cancer Research